• Citer

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

par Dumez, Herlinde;Awada, Ahmad ;Piccart-Gebhart, Martine ;Assadourian, S;Semiond, D;Guetens, G;De Boeck, Geneviève ;Maes, R A A;de Bruijn, E A;van Oosterom, A
Référence Annals of oncology, 17, 7, page (1158-1165)
Publication Publié, 2006-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Auteur:	Dumez, Herlinde; Awada, Ahmad; Piccart-Gebhart, Martine; Assadourian, S; Semiond, D; Guetens, G; De Boeck, Geneviève; Maes, R A A; de Bruijn, E A; van Oosterom, A
Informations sur la publication:	Annals of oncology, 17, 7, page (1158-1165)
Statut de publication:	Publié, 2006-07
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	CPT-11
	Dose-escalation
	Dose-limiting toxicity
	Irinotecan
	Oral
	Powder-filled capsule
MeSH keywords:	Administration, Oral
	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Agents, Phytogenic -- administration & dosage
	Antineoplastic Agents, Phytogenic -- adverse effects
	Antineoplastic Agents, Phytogenic -- pharmacokinetics
	Area Under Curve
	Camptothecin -- administration & dosage
	Camptothecin -- analogs & derivatives
	Camptothecin -- pharmacokinetics
	Camptothecin -- toxicity
	DNA Topoisomerases, Type I -- antagonists & inhibitors
	Female
	Humans
	Male
	Middle Aged
	Neoplasms -- drug therapy
Note générale:	Clinical Trial, Phase I
	Journal Article
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdl071
	info:pii/mdl071
	info:scp/33745587557
	info:pmid/16600980